DEPAKOTE CP
LOE ApproachingNDAORALTABLET, DELAYED RELEASE
Approved
Jul 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEPAKOTE CP (divalproex sodium) is a delayed-release oral tablet approved in 1990 for neurological and psychiatric indications. The mechanism of action involves modulation of GABA neurotransmission and histone deacetylase inhibition. It is used primarily in epilepsy, bipolar disorder, and migraine prophylaxis.
LOE Approaching
Product is approaching loss of exclusivity; commercial teams are likely focused on lifecycle extension, generic transition planning, and cost optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DEPAKOTE CP offers limited career growth potential given the LOE-approaching lifecycle stage and minimal linked job opportunities. Professionals on this team gain expertise in lifecycle management, generic transition strategy, and mature market optimization rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on DEPAKOTE CP at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.